{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:00:13Z","timestamp":1790229613797,"version":"4.1.0"},"reference-count":173,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Tuberculosis (TB) continues to be a major global health challenge, largely due to\nthe complex nature of Mycobacterium tuberculosis. Its early detection and effective management\nare heavily reliant on advanced diagnostic methods. New drug delivery systems and repurposing\nexisting drugs show great promise in improving TB treatment. This study explores\nthe progress and hurdles in developing anti-TB drugs, focusing on those currently in clinical\ntrials. Additionally, innovative approaches like immunotherapy, combination therapy, and adjunct\ntherapy, which include the use of phytochemicals, are examined for their potential to enhance\ntreatment outcomes and tackle drug resistance. These innovative approaches could be\nthe key to the future of the fight against TB. It also highlights how these strategies could accelerate\nTB treatment. It incorporates public health strategies for preventing TB transmission\nand ensuring patients adhere to treatments. By addressing these key areas, this work aims to\ncontribute to the global fight against TB and improve the lives of those affected by the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010355430250330074301","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:25:21Z","timestamp":1744781121000},"page":"963-987","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combating TB Pathology: Advanced Diagnostics, Innovative Therapies, and Public Health Strategies: A Review"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6665-3432","authenticated-orcid":true,"given":"Satyajit","family":"Mohanty","sequence":"first","affiliation":[{"name":"Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology,Mesra, Ranchi, 835215, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet Kaur","family":"Khanna","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University, Sector14, Chandigarh, 160014, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnendu","family":"Adhikary","sequence":"additional","affiliation":[{"name":"Department of Interdisciplinary Science, Centurion University of Technology andManagement, Odisha, 761211, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhin","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology,Mesra, Ranchi, 835215, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwesha","family":"Sahu","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology,Mesra, Ranchi, 835215, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Kahwa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, Pharm-Biotechnology and TraditionalMedicine Centre of Excellence (ACEII), Mbarara University of Science and Technology, Mbarara, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav Kumar","family":"Prabhakar","sequence":"additional","affiliation":[{"name":"Research and Development, Parul University, Post Limda, Waghodia, Gujarat, 391760, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahendra Pratap","family":"Swain","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology,Mesra, Ranchi, 835215, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anasuya","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Division of PharmaceuticalChemistry, Sri Jayadev College of Pharmaceutical Sciences, Bhubaneswar, Odisha, 752101, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Parida","sequence":"additional","affiliation":[{"name":"Division ofPharmacognosy, Sri Medical Science and Pharmacy College, Nayagarh, Odisha, 752090, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/cid\/civ609","volume":"61","author":"Schito M","year":"2015","unstructured":"Schito M; Migliori GB; Fletcher HA; McNerney R; Centis R; D'Ambrosio L; Bates M; Kibiki G; Kapata N; Corrah T; Bomanji J; Vilaplana C; Johnson D; Mwaba P; Maeurer M; Zumla A; Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines. Clin Infect Dis  2015,61(61)(Suppl. 3),S102-S118","journal-title":"Clin Infect Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jiph.2015.10.008","volume":"9","author":"Prakash R.","year":"2016","unstructured":"Prakash R.; Kumar D.; Gupta V.K.; Jain S.; Chauhan D.S.; Tiwari P.K.; Katoch V.M.; Status of multidrug resistant tuberculosis (MDR-TB) among the Sahariya tribe of North Central India. J Infect Public Health  2016,9(3),289-297","journal-title":"J Infect Public Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5588\/ijtld.17.0355","volume":"22","author":"Garcia-Prats A.J.","year":"2018","unstructured":"Garcia-Prats A.J.; Svensson E.M.; Weld E.D.; Schaaf H.S.; Hesseling A.C.; Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children. Int J Tuberc Lung Dis  2018,22(5),15-23","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=4","first-page":"72","volume":"66","author":"Karekar S.R.","year":"2018","unstructured":"Karekar S.R.; Marathe P.A.; Current status of delamanid in the management of MDR tuberculosis. J Assoc Physicians India  2018,66(7),72-75","journal-title":"J Assoc Physicians India"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e0245686","DOI":"10.1371\/journal.pone.0245686","volume":"16","author":"Gautam N.","year":"2021","unstructured":"Gautam N.; Karki R.R.; Khanam R.; Knowledge on tuberculosis and utilization of DOTS service by tuberculosis patients in Lalitpur District, Nepal. PLoS One  2021,16(1),e0245686","journal-title":"PLoS One"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e0117361","DOI":"10.1371\/journal.pone.0117361","volume":"10","author":"Yang X.","year":"2015","unstructured":"Yang X.; Yuan Y.; Pang Y.; Wang B.; Bai Y.; Wang Y.; Yu B.; Zhang Z.; Fan M.; Zhao Y.; The burden of MDR\/XDR tuberculosis in coastal plains population of China. PLoS One  2015,10(2),e0117361","journal-title":"PLoS One"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e50923","DOI":"10.1371\/journal.pone.0050923","volume":"7","author":"Pinheiro M.B.","year":"2012","unstructured":"Pinheiro M.B.; Antonelli L.R.; Sathler-Avelar R.; Vitelli-Avelar D.M.; Spindola-de-Miranda S.; Guimar\u00e3es T.M.P.D.; Teixeira-Carvalho A.; Martins-Filho O.A.; Toledo V.P.C.P.; CD4-CD8-\u03b1\u03b2 and \u03b3\u03b4 T cells display inflammatory and regulatory potentials during human tuberculosis. PLoS One  2012,7(12),e50923","journal-title":"PLoS One"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12931-017-0580-3","volume":"18","author":"Shu C.C.","year":"2017","unstructured":"Shu C.C.; Wu M.F.; Wang J.Y.; Lai H.C.; Lee L.N.; Chiang B.L.; Yu C.J.; Decreased T helper 17 cells in tuberculosis is associated with increased percentages of programmed death ligand 1, T helper 2 and regulatory T cells. Respir Res  2017,18(1),128","journal-title":"Respir Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1172\/JCI128043","volume":"130","author":"Fatima S.","year":"2019","unstructured":"Fatima S.; Kamble S.S.; Dwivedi V.P.; Bhattacharya D.; Kumar S.; Ranganathan A.; Van Kaer L.; Mohanty S.; Das G.; Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and persistence. J Clin Invest  2019,130(2),655-661","journal-title":"J Clin Invest"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7860\/JCDR\/2014\/7416.3975","volume":"8","author":"P K C.","year":"2014","unstructured":"P K C.; Nagaral J.; M N N.; G P.; B R H.; Vinaykumar M.V.; TB-DOTS outcome in relation to HIV status: Experience in a medical college. J Clin Diagn Res  2014,8(1),74-76","journal-title":"J Clin Diagn Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/AAC.02600-15","volume":"60","author":"Bekker A.","year":"2016","unstructured":"Bekker A.; Schaaf H.S.; Draper H.R.; van der Laan L.; Murray S.; Wiesner L.; Donald P.R.; McIlleron H.M.; Hesseling A.C.; Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother  2016,60(4),2171-2179","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/1120009X.2020.1716479","volume":"32","author":"Haratiasl A.A.","year":"2020","unstructured":"Haratiasl A.A.; Hamzelou G.; Amini S.; Kardan-Yamchi J.; Haeili M.; Heidari F.; Feizabadi M.M.; Molecular identification of mutations conferring resistance to rifampin, isoniazid and pyrazinamide among Mycobacterium tuberculosis isolates from Iran. J Chemother  2020,32(2),75-82","journal-title":"J Chemother"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40794-018-0065-5","volume":"4","author":"Girum T.","year":"2018","unstructured":"Girum T.; Muktar E.; Lentiro K.; Wondiye H.; Shewangizaw M.; Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: A systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines  2018,4(1),5","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2012.18","volume":"1","author":"Zhang Y.","year":"2012","unstructured":"Zhang Y.; Chiu Chang K.; Leung C.C.; Wai Yew W.; Gicquel B.; Fallows D.; Kaplan G.; Chaisson R.E.; Zhang W.; \u2018Z  -MDR-TB\u2019 versus \u2018Z  -MDR-TB\u2019: Improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microbes Infect  2012,1(1),1-4","journal-title":"Emerg Microbes Infect"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/1469-0691.12253","volume":"19","author":"Borgdorff M.W.","year":"2013","unstructured":"Borgdorff M.W.; van Soolingen D.; The re-emergence of tuberculosis: What have we learnt from molecular epidemiology? Clin Microbiol Infect  2013,19(10),889-901","journal-title":"Clin Microbiol Infect"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e1001189","DOI":"10.1371\/journal.ppat.1001189","volume":"7","author":"Stein C.M.","year":"2011","unstructured":"Stein C.M.; Genetic epidemiology of tuberculosis susceptibility: Impact of study design. PLoS Pathog  2011,7(1),e1001189","journal-title":"PLoS Pathog"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0213-005X(11)70012-X","volume":"29","author":"Garc\u00eda de Viedma D.","year":"2011","unstructured":"Garc\u00eda de Viedma D.; Mokrousov I.; Rastogi N.; Innovations in the molecular epidemiology of tuberculosis. Enferm Infecc Microbiol Clin  2011,29(Suppl. 1),8-13","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.meegid.2019.01.027","volume":"72","author":"Garc\u00eda de Viedma D.","year":"2019","unstructured":"Garc\u00eda de Viedma D.; Pathways and strategies followed in the genomic epidemiology of Mycobacterium tuberculosis. Infect Genet Evol  2019,72,4-9","journal-title":"Infect Genet Evol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11684-017-0609-5","volume":"12","author":"Yang C.","year":"2018","unstructured":"Yang C.; Gao Q.; Recent transmission of Mycobacterium tuberculosis in China: The implication of molecular epidemiology for tuberculosis control. Front Med  2018,12(1),76-83","journal-title":"Front Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ccm.2005.02.005","volume":"26","author":"Daley C.L.","year":"2005","unstructured":"Daley C.L.; Molecular epidemiology: A tool for understanding control of tuberculosis transmission. Clin Chest Med  2005,26(2),217-231, vi","journal-title":"Clin Chest Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eimce.2017.10.009","volume":"36","author":"Cardona P.J.","year":"2018","unstructured":"Cardona P.J.; Pathogenesis of tuberculosis and other mycobacteriosis. Enferm Infecc Microbiol Clin (Engl Ed)  2018,36(1),38-46","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00148581-200507040-00002","volume":"7","author":"Skevaki C.L.","year":"2005","unstructured":"Skevaki C.L.; Kafetzis D.A.; Tuberculosis in neonates and infants: Epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues. Paediatr Drugs  2005,7(4),219-234","journal-title":"Paediatr Drugs"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0041-3879(82)80036-6","volume":"63","author":"Dam H.G.","year":"1982","unstructured":"Dam H.G.; Pio A.; Pathogenesis of tuberculosis and effectiveness of BCG vaccination. Tubercle  1982,63(3),225-233","journal-title":"Tubercle"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1164\/artpd.1956.73.3.362","volume":"73","author":"Lack C.H.","year":"1956","unstructured":"Lack C.H.; The pathogenesis of tuberculosis as shown in studies of omental spreads. Am Rev Tuberc  1956,73(3),362-377","journal-title":"Am Rev Tuberc"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"S366","DOI":"10.1093\/clinids\/11.Supplement_2.S366","volume":"11","author":"Stead W.W.","year":"1989","unstructured":"Stead W.W.; Pathogenesis of tuberculosis: Clinical and epidemiologic perspective. Clin Infect Dis  1989,11(2),S366-S368","journal-title":"Clin Infect Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1134\/S000629792114008X","volume":"86","author":"Ostrik A.A.","year":"2021","unstructured":"Ostrik A.A.; Azhikina T.L.; Salina E.G.; Small noncoding RNAs and their role in the pathogenesis of Mycobacterium tuberculosis infection. Biochemistry (Mosc)  2021,86(S1)(Suppl. 1),S109-S119","journal-title":"Biochemistry (Mosc)"},{"key":"ref=27","first-page":"934","volume":"45","author":"Peng Q","year":"2023","unstructured":"Peng Q; Wu N; Huang Y; Zhao SJ; Tang W; Liang M; Ran YL; Xiao T; Yang L; Liang X; Diagnostic values of conventional tumor markers and their combination with chest CT for patients with stage\u2160A lung cancer. Chin Med J  2023,45(11),934-941","journal-title":"Chin Med J"},{"key":"ref=28","first-page":"697","volume":"45","author":"Song SB","year":"2023","unstructured":"Song SB; Dou LZ; Liu Y; Zhang YM; He S; Wang GQ; Endoscopic hand-suturing combined with titanium clips for rectal defects closure after endoscopic submucosal dissection: a pilot study. Chin Med J  2023,45(8),697-703","journal-title":"Chin Med J"},{"key":"ref=29","first-page":"584","volume":"57","author":"Xie TC","year":"2023","unstructured":"Xie TC; Tang J; He QR; Wang WP; Wang C; Research progress in transcriptional and immunological biomarkers associated with tuberculosis infection. Chin J Prev Med  2023,57(4),584-590","journal-title":"Chin J Prev Med"},{"key":"ref=30","first-page":"1090","volume":"99","author":"Ma Y","year":"2019","unstructured":"Ma Y; Du J; Shu W; Xie SH; Wang HH; Tan SY; Li XQ; Fu YY; Ma LP; Zhang LY; Liu FY; Hu DY; Zhang YL; Liu YH; Li L; Effect of alcohol drinking on sputum conversion at the end of second month and outcome of smear-positive pulmonary tuberculosis patients. Chin Med J  2019,99(14),1090-1094","journal-title":"Chin Med J"},{"key":"ref=31","first-page":"103","volume":"51","author":"Li L","year":"2021","unstructured":"Li L; Gao JT; The tuberculosis sanitariums during era of the Republic of China. Chin Med J  2021,51(2),103-110","journal-title":"Chin Med J"},{"key":"ref=32","first-page":"1653","volume":"44","author":"Cao B","year":"2023","unstructured":"Cao B; Fan XT; Wang RH; Luan XL; Qian CY; Yu JJ; Liu HC; Li MC; Li GL; Zhao XQ; Yuan XQ; Wan KL; Preliminary evaluation of immunogenicity and protective effect of multicomponent recombinant protein vaccine EPRHP014 against tuberculosis. Chin Med J  2023,44(10),1653-1660","journal-title":"Chin Med J"},{"key":"ref=33","first-page":"470","volume":"44","author":"Wang Z","year":"2023","unstructured":"Wang Z; Wang WJ; Ding XY; Lu P; Zhu LM; Liu Q; Lu W; Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients. Chin Med J  2023,44(3),470-476","journal-title":"Chin Med J"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3349\/ymj.2020.61.9.789","volume":"61","author":"Kim A.","year":"2020","unstructured":"Kim A.; Park K.J.; Kim Y.S.; Cho S.N.; Dockrell H.M.; Hur Y.G.; Diagnostic potential of a PPE protein derived from Mycobacterium tuberculosis Beijing\/K Strain. Yonsei Med J  2020,61(9),789-796","journal-title":"Yonsei Med J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/21505594.2022.2080342","volume":"13","author":"Liang Z.","year":"2022","unstructured":"Liang Z.; Li H.; Qu M.; Liu Y.; Wang Y.; Wang H.; Dong Y.; Chen Y.; Ge X.; Zhou X.; Intranasal bovine \u03b2-defensin-5 enhances antituberculosis immunity in a mouse model by a novel protein-based respiratory mucosal vaccine. Virulence  2022,13(1),949-962","journal-title":"Virulence"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.14202\/vetworld.2022.2376-2383","volume":"15","author":"Fihiruddin F.","year":"2022","unstructured":"Fihiruddin F.; Inayati N.; Jannah R.; Unsunnidhal L.; Kusumawati A.; Expression and epitope prediction of MPT64 recombinant proteins from clinical isolates of Mycobacterium tuberculosis as immunoserodiagnostic candidates. Vet World  2022,15(10),2376-2383","journal-title":"Vet World"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13567-019-0702-7","volume":"50","author":"Roy A.","year":"2019","unstructured":"Roy A.; Tom\u00e9 I.; Romero B.; Lorente-Leal V.; Infantes-Lorenzo J.A.; Dom\u00ednguez M.; Mart\u00edn C.; Aguil\u00f3 N.; Puentes E.; Rodr\u00edguez E.; de Juan L.; Risalde M.A.; Gort\u00e1zar C.; Dom\u00ednguez L.; Bezos J.; Evaluation of the immunogenicity and efficacy of BCG and MTBVAC vaccines using a natural transmission model of tuberculosis. Vet Res  2019,50(1),82","journal-title":"Vet Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/vr.l6839","volume":"185","author":"Bovine T.B.","year":"2019","unstructured":"Bovine T.B.; Bovine TB: Researchers adapt the BCG vaccine for cattle use. Vet Rec  2019,185(22),676-677","journal-title":"Vet Rec"},{"key":"ref=39","first-page":"385","volume":"54","author":"Gao L","year":"2020","unstructured":"Gao L; Quan ZS; Cheng J; Jin Q; Application of two-step approach for tuberculosis infection testing in tuberculosis control in schools. Chin J Prev Med  2020,54(4),385-391","journal-title":"Chin J Prev Med"},{"key":"ref=40","first-page":"318","volume":"48","author":"Yang H","year":"2014","unstructured":"Yang H; Hu Z; Sha W; Lu J; Cui Z; Wang J; Huang X; Xiao H.; Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin. Chin J Prev Med  2014,48(4),318-323","journal-title":"Chin J Prev Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e0225042","DOI":"10.1371\/journal.pone.0225042","volume":"14","author":"Xu J.","year":"2019","unstructured":"Xu J.; Wang G.; Zhang Y.; Zhang G.; Xing J.; Qi L.; Zhuang Y.; Zeng H.; Chang J.; An outbreak of tuberculosis in a middle school in Henan, China: Epidemiology and risk factors. PLoS One  2019,14(11),e0225042","journal-title":"PLoS One"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e0221145","DOI":"10.1371\/journal.pone.0221145","volume":"14","author":"Oliwa J.N.","year":"2019","unstructured":"Oliwa J.N.; Gathara D.; Ogero M.; van Hensbroek M.B.; English M.; van\u2019t Hoog A.; Diagnostic practices and estimated burden of tuberculosis among children admitted to 13 government hospitals in Kenya: An analysis of two years\u2019 routine clinical data. PLoS One  2019,14(9),e0221145","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","volume":"20","author":"Zhou G.","year":"2020","unstructured":"Zhou G.; Luo Q.; Luo S.; Teng Z.; Ji Z.; Yang J.; Wang F.; Wen S.; Ding Z.; Li L.; Chen T.; Abi M.E.; Jian M.; Luo L.; Liu A.; Bao F.; Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: A systematic review and meta-analysis. Lancet Infect Dis  2020,20(12),1457-1469","journal-title":"Lancet Infect Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"20.1.13","DOI":"10.1128\/jmbe.v20i1.1649","volume":"20","author":"Mangayarkarasi V","year":"2019","unstructured":"Mangayarkarasi V; Kalaiselvi K; Kavitha D; Chitraleka V; Balaji R.; Program-based teaching and learning to increase competency in undergraduate medical students using a model of the revised national tuberculosis control program.  J Microbiol Biol Educ  2019,20(1),20.1.13","journal-title":"J Microbiol Biol Educ"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.18240\/ijo.2020.11.09","volume":"13","author":"Annamalai R.","year":"2020","unstructured":"Annamalai R.; Mohanakumar M.; Raghu K.; Muthayya M.; Newer trends in tubercular uveitis: A case series with systemic correlation. Int J Ophthalmol  2020,13(11),1739-1744","journal-title":"Int J Ophthalmol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/ijd.15737","volume":"60","author":"Singal A.","year":"2021","unstructured":"Singal A.; Kaur I.; Pandhi D.; Gandhi V.; Jakhar D.; Grover C.; Clinico\u2010epidemiological profile of lichen scrofulosorum: A 22\u2010year, single\u2010center, retrospective study. Int J Dermatol  2021,60(10),1278-1284","journal-title":"Int J Dermatol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/zph.12814","volume":"68","author":"Saadi A.","year":"2021","unstructured":"Saadi A.; Antoine-Moussiaux N.; Marcotty T.; Thys S.; Sahibi H.; Using qualitative approaches to explore the challenges of integrated programmes for zoonosis control in developing countries: Example of hydatidosis control in Morocco. Zoonoses Public Health  2021,68(5),393-401","journal-title":"Zoonoses Public Health"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/zph.12684","volume":"67","author":"Luciano S.A.","year":"2020","unstructured":"Luciano S.A.; Roess A.; Human zoonotic tuberculosis and livestock exposure in low\u2010 and middle\u2010income countries: A systematic review identifying challenges in laboratory diagnosis. Zoonoses Public Health  2020,67(2),97-111","journal-title":"Zoonoses Public Health"},{"key":"ref=49","first-page":"1160","volume":"57","author":"Zhang C","year":"2023","unstructured":"Zhang C; Zhuoga RZG; Sangmu LSM; Zhong B; Zhao XQ; Ouyang HW; Deng SM; Zhuoma WZM; Epidemiological characteristics of pulmonary tuberculosis in Motuo County, Tibet Autonomous region from 2012 to 2021. Chin J Prev Med  2023,57(8),1160-1163","journal-title":"Chin J Prev Med"},{"key":"ref=50","first-page":"1153","volume":"57","author":"Yu XR","year":"2023","unstructured":"Yu XR; Wang SJ; Yang XM; Fang M; Zeng X; Qi H; Jiao WW; Sun L; Analysis of changes in reporting and diagnosis of pulmonary tuberculosis among children in Liangshan Yi autonomous prefecture, Sichuan province from 2019 to 2021. Chin J Prev Med  2023,57(8),1153-1159","journal-title":"Chin J Prev Med"},{"key":"ref=51","first-page":"1486","volume":"55","author":"Xie JH","year":"2021","unstructured":"Xie JH; Yu R; Shi GM; Ma XH; Xiao SF; Yi YH; Zhou T; Xiang YG; Correlation study between changes in intestinal microflora structure and immune indexes in newly treated patients with pulmonary tuberculosis. Chin J Prev Med  2021,55(12),1486-1490","journal-title":"Chin J Prev Med"},{"key":"ref=52","first-page":"1410","volume":"55","author":"Wang M","year":"2021","unstructured":"Wang M; Zhao JY; Li X; Wu LY; Zhou QQ; Huang YF; Sui WJ; Zhang SY; Xu J; Jin JM; Gu HT; Lu XX; Study on the etiological characteristics and prevention and control of adult community-acquired pneumonia in hospitalized patients in a hospital in Beijing from 2015 to 2019. Chin J Prev Med  2021,55(12),1410-1418","journal-title":"Chin J Prev Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12916-016-0617-3","volume":"14","author":"Fletcher H.A.","year":"2016","unstructured":"Fletcher H.A.; Filali-Mouhim A.; Nemes E.; Hawkridge A.; Keyser A.; Njikan S.; Hatherill M.; Scriba T.J.; Abel B.; Kagina B.M.; Veldsman A.; Agudelo N.M.; Kaplan G.; Hussey G.D.; Sekaly R.P.; Hanekom W.A.; Human newborn bacille Calmette\u2013Gu\u00e9rin vaccination and risk of tuberculosis disease: A case-control study. BMC Med  2016,14(1),76","journal-title":"BMC Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13690-024-01326-0","volume":"82","author":"Shah  A.P.","year":"2024","unstructured":"Shah A.P.; Dave J.D.; Makwana M.N.; Rupani M.P.; Shah I.A.; A mixed-methods study on impact of active case finding on pulmonary tuberculosis treatment outcomes in India. Arch Public Health  2024,82(1),92","journal-title":"Arch Public Health"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e72470","DOI":"10.1371\/journal.pone.0072470","volume":"8","author":"Begun M.","year":"2013","unstructured":"Begun M.; Newall A.T.; Marks G.B.; Wood J.G.; Contact tracing of tuberculosis: A systematic review of transmission modelling studies. PLoS One  2013,8(9),e72470","journal-title":"PLoS One"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40506-017-0135-7","volume":"9","author":"Tang P.","year":"2017","unstructured":"Tang P.; Johnston J.; Treatment of latent tuberculosis infection. Curr Treat Options Infect Dis  2017,9(4),371-379","journal-title":"Curr Treat Options Infect Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"CD013582","DOI":"10.1002\/14651858.CD013582","volume":"2020","author":"Houghton C.","year":"2020","unstructured":"Houghton C.; Meskell P.; Delaney H.; Smalle M.; Glenton C.; Booth A.; Chan X.H.S.; Devane D.; Biesty L.M.; Barriers and facilitators to healthcare workers\u2019 adherence with infection prevention and control (IPC) guidelines for respiratory infectious diseases: A rapid qualitative evidence synthesis. Cochrane Libr  2020,2020(8),CD013582","journal-title":"Cochrane Libr"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1097\/01.olq.0000180453.31255.2d","volume":"32","author":"Taylor M.","year":"2005","unstructured":"Taylor M.; Montoya J.A.; Cantrell R.; Mitchell S.J.; Williams M.; Jordahl L.; Freeman M.; Brown J.; Broussard D.; Roland E.; Interventions in the commercial sex industry during the rise in syphilis rates among men who have sex with men (MSM). Sex Transm Dis  2005,32(10)(Suppl. 10),S53-S59","journal-title":"Sex Transm Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2105\/AJPH.2010.199505","volume":"101","author":"Hargreaves  J.R.","year":"2011","unstructured":"Hargreaves J.R.; Boccia D.; Evans C.A.; Adato M.; Petticrew M.; Porter J.D.;  The social determinants of tuberculosis: From evidence to action. Am J Public Health  2011,101(4),654-662","journal-title":"Am J Public Health"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0970-2113.45198","volume":"26","author":"Gupta K.","year":"2009","unstructured":"Gupta K.; Gupta R.; Atreja A.; Verma M.; Vishvkarma S.; Tuberculosis and nutrition. Lung India  2009,26(1),9-16","journal-title":"Lung India"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12914-014-0028-5","volume":"14","author":"Sambo L.G.","year":"2014","unstructured":"Sambo L.G.; Kirigia J.M.; Investing in health systems for universal health coverage in Africa. BMC Int Health Hum Rights  2014,14(1),28","journal-title":"BMC Int Health Hum Rights"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e17027","DOI":"10.1097\/MD.0000000000017027","volume":"98","author":"Chang L.","year":"2019","unstructured":"Chang L.; Su Y.; Zhu R.; Duan Z.; Mapping international collaboration in tuberculosis research from 1998 to 2017. Medicine (Baltimore)  2019,98(37),e17027","journal-title":"Medicine (Baltimore)"},{"key":"ref=63","first-page":"2525","volume":"100","author":"Tang XZ","year":"2020","unstructured":"Tang XZ; Huang T; Ma Y; Fu XY; Qian K; Yi YL; Wu GH; Meta-analysis of efficacy and safety of vitamin D supplementation in the treatment of pulmonary tuberculosis. Chin Med J  2020,100(32),2525-2531","journal-title":"Chin Med J"},{"key":"ref=64","first-page":"210","volume":"42","author":"Hu XL","year":"2024","unstructured":"Hu XL; Wang SQ; A case of silicosis complicated with non-tuberculous mycobacterium pulmonary disease. Chinese J Industr Hygien Occupation Diseases  2024,42(3),210-212","journal-title":"Chinese J Industr Hygien Occupation Diseases"},{"key":"ref=65","first-page":"690","volume":"37","author":"Jin Y","year":"2019","unstructured":"Jin Y; Wang HQ; Fan JG; Pang J; Zhang PY; Li T; Evaluation of GeneXpert MTB\/RIF and BACTEC-MGIT 960 for the detection of tuberculosis among pneumoconiosis-associated tuberculosis patients. Chinese J Industr Hygien Occupation Diseases  2019,37(9),690-693","journal-title":"Chinese J Industr Hygien Occupation Diseases"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3760\/cma.j.cn112147-20230814-00074","volume":"47","author":"Zhang TH","year":"2024","unstructured":"Zhang TH; Ma ZC; Liu RM; Shang YY; Ma LP; Han M; Pang Y; Evaluation of the efficacy of urine-based lipoarabinomannan antigen test in the diagnosis of pulmonary tuberculosis. Chinese J Tuberculosis Resp Dis  2024,47(2),132","journal-title":"Chinese J Tuberculosis Resp Dis"},{"key":"ref=67","first-page":"552","volume":"45","author":"Liu YY","year":"2022","unstructured":"Liu YY; Shi J; Chu P; Wu TY; Li L; Pang Y; Lu J; Guo YL; Exploratory study on detection of drug resistance of Mycobacterium tuberculosis in sputum specimens by next-generation sequencing. Chinese J Tuberculosis Resp Dis  2022,45(6),552-559","journal-title":"Chinese J Tuberculosis Resp Dis"},{"key":"ref=68","first-page":"96","volume":"44","author":"Sun WW","year":"2021","unstructured":"Sun WW; Gu J; Fan L; Application value of metagenomic next-generation sequencing (mNGS) in the diagnosis of different types of tuberculosis. Chinese J Tuberculosis Resp Dis  2021,44(2),96-100","journal-title":"Chinese J Tuberculosis Resp Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11274-023-03564-w","volume":"39","author":"Kooti S.","year":"2023","unstructured":"Kooti S.; Kadivarian S.; Abiri R.; Mohajeri P.; Atashi S.; Ahmadpor H.; Alvandi A.; Modified gold nanoparticle colorimetric probe-based biosensor for direct and rapid detection of Mycobacterium tuberculosis in sputum specimens. World J Microbiol Biotechnol  2023,39(5),118","journal-title":"World J Microbiol Biotechnol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"102514","DOI":"10.1016\/j.tube.2024.102514","volume":"147","author":"Njagi L.N.","year":"2024","unstructured":"Njagi L.N.; Kaguthi G.; Mecha J.O.; Hawn T.R.; Nduba V.; Attenuated tuberculin skin test responses associated with Mycobacterium intracellulare sputum colonization in an adolescent TB prevalence survey in Western Kenya. Tuberculosis (Edinb)  2024,147,102514","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=71","first-page":"764","volume":"41","author":"Chen R","year":"2020","unstructured":"Chen R; Li MC; Zhao LL; Zhao XQ; Liu HC; Liu ZG; Lu Y; Deng YL; Chen ZX; Wan KL; Yuan XQ; Analysis on drug sensitivity spectrum of 167 multidrug-resistant Mycobacterium tuberculosis in China. Chinese J Tuberculosis Resp Dis  2020,41(5),764-769","journal-title":"Chinese J Tuberculosis Resp Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.21037\/jtd.2018.02.60","volume":"10","author":"Wang G.","year":"2018","unstructured":"Wang G.; Wang S.; Jiang G.; Fu Y.; Shang Y.; Huang H.; Incremental cost-effectiveness of the second Xpert MTB\/RIF assay to detect Mycobacterium tuberculosis J Thorac Dis  2018,10(3),1689-1695","journal-title":"J Thorac Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13567-020-00881-y","volume":"52","author":"Thomas J.","year":"2021","unstructured":"Thomas J.; Balseiro A.; Gort\u00e1zar C.; Risalde M.A.; Diagnosis of tuberculosis in wildlife: A systematic review. Vet Res  2021,52(1),31","journal-title":"Vet Res"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/vms3.134","volume":"5","author":"Infantes-Lorenzo J.A.","year":"2019","unstructured":"Infantes-Lorenzo J.A.; Dave D.; Moreno I.; Anderson P.; Lesellier S.; Gormley E.; Dominguez L.; Balseiro A.; Gort\u00e1zar C.; Dominguez M.; Salguero F.J.; New serological platform for detecting antibodies against Mycobacterium tuberculosis complex in European badgers. Vet Med Sci  2019,5(1),61-69","journal-title":"Vet Med Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.62438\/tunismed.v102i1.4521","volume":"102","author":"Tritar F.","year":"2024","unstructured":"Tritar F.; Ben Saad S.; Ferchichi M.; Ben Mansour A.; Slim A.; Naffati O.; Bellali H.; Slim L.; Daghfous H.; Risk factors for treatment failure in multidrug resistant tuberculosis in Tunisia: An analytic study. Tunis Med  2024,102(1),44-48","journal-title":"Tunis Med"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5578\/tt.20219703","volume":"69","author":"\u00dcnl\u00fc N","year":"2021","unstructured":"\u00dcnl\u00fc N; Can Sar\u0131no\u011flu R; Duman N; K\u00fc\u00e7\u00fcksu U; Karahasan Ya\u011fc\u0131 A.; Evaluation of the molecular assays for detection of Mycobacterium tuberculosis complex in extrapulmonary specimens. Tuberk Toraks  2021,69(3),314-320","journal-title":"Tuberk Toraks"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5578\/tt.20219805","volume":"69","author":"Hasbek M","year":"2021","unstructured":"Hasbek M; Ta\u015fk\u0131n Kafa AH; \u00c7elik C; Evaluation of the diagnostic performance of the Xpert MTB\/RIF assay in pulmonary and extrapulmonary samples. Tuberk Toraks  2021,69(2),160-166","journal-title":"Tuberk Toraks"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"102515","DOI":"10.1016\/j.tube.2024.102515","volume":"147","author":"Singhal R.","year":"2024","unstructured":"Singhal R.; Hingane S.; Bhalla M.; Sharma A.; Ferdosh S.; Tiwari A.; Jayaswal P.; Yadav R.N.; Arora J.; Dewan R.K.; Sharma S.; Evaluation of AAICare-TB sequence analysis tool for accurate diagnosis of drug-resistant tuberculosis: A comparative study with TB-Profiler and Mykrobe. Tuberculosis (Edinb)  2024,147,102515","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"102349","DOI":"10.1016\/j.tube.2023.102349","volume":"140","author":"Fan D.","year":"2023","unstructured":"Fan D.; Yue Y.; Li H.; Shang X.; Li H.; Xiao R.; Cai L.; Evaluation of the performances of InnowaveDx MTB-RIF assay in the diagnosis of pulmonary tuberculosis using bronchoalveolar lavage fluid. Tuberculosis (Edinb)  2023,140,102349","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.tube.2022.102273","volume":"137","author":"Rodriguez J","year":"2022","unstructured":"Rodriguez J; Alc\u00e1ntara R; Rodr\u00edguez J; Vargas J; Roncal E; Antiparra R; Gilman RH; Grandjean L; Moore D; Zimic M; Sheen P; Evaluation of three alternatives cost-effective culture media for Mycobacterium tuberculosis detection and drug susceptibility determination using the microscopic observation drug susceptibility (MODS) assay. Tuberculosis (Edinb)  2022,137,102273","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"102209","DOI":"10.1016\/j.tube.2022.102209","volume":"135","author":"Shi J.","year":"2022","unstructured":"Shi J.; He G.; Ning H.; Wu L.; Wu Z.; Ye X.; Qiu C.; Jiang X.; Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. Tuberculosis (Edinb)  2022,135,102209","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"102051","DOI":"10.1016\/j.tube.2021.102051","volume":"127","author":"Kambli P.","year":"2021","unstructured":"Kambli P.; Ajbani K.; Kazi M.; Sadani M.; Naik S.; Shetty A.; Tornheim J.A.; Singh H.; Rodrigues C.; Targeted next generation sequencing directly from sputum for comprehensive genetic information on drug resistant Mycobacterium tuberculosis Tuberculosis (Edinb)  2021,127,102051","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"101994","DOI":"10.1016\/j.tube.2020.101994","volume":"125","author":"Haiqing Cai","year":"2020","unstructured":"Haiqing Cai ; Chen L.; Yin C.; Liao Y.; Meng X.; Lu C.; Tang S.; Li X.; Wang X.; The effect of micro-nutrients on malnutrition, immunity and therapeutic effect in patients with pulmonary tuberculosis: A systematic review and meta\u2010analysis of randomised controlled trials. Tuberculosis (Edinb)  2020,125,101994","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=84","first-page":"695","volume":"135","author":"Steingart K.R.","year":"2012","unstructured":"Steingart K.R.; Ramsay A.; Dowdy D.W.; Pai M.; Serological tests for the diagnosis of active tuberculosis: Relevance for India. Indian J Med Res  2012,135(5),695-702","journal-title":"Indian J Med Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/thx.2006.075754","volume":"83","author":"Steingart K.R.","year":"2007","unstructured":"Steingart K.R.; Henry M.; Laal S.; Hopewell P.C.; Ramsay A.; Menzies D.; Cunningham J.; Weldingh K.; Pai M.; A systematic review of commercial serological antibody detection tests for the diagnosis of extrapulmonary tuberculosis. Postgrad Med J  2007,83(985),705-712","journal-title":"Postgrad Med J"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1371\/journal.pmed.0040202","volume":"4","author":"Steingart K.R.","year":"2007","unstructured":"Steingart K.R.; Henry M.; Laal S.; Hopewell P.C.; Ramsay A.; Menzies D.; Cunningham J.; Weldingh K.; Pai M.; Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: A systematic review. PLoS Med  2007,4(6),e202","journal-title":"PLoS Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jim.2005.04.004","volume":"301","author":"Tong M.","year":"2005","unstructured":"Tong M.; Jacobi C.E.; van de Rijke F.M.; Kuijper S.; van de Werken S.; Lowary T.L.; Hokke C.H.; Appelmelk B.J.; Nagelkerke N.J.D.; Tanke H.J.; van Gijlswijk R.P.M.; Veuskens J.; Kolk A.H.J.; Raap A.K.; A multiplexed and miniaturized serological tuberculosis assay identifies antigens that discriminate maximally between TB and non-TB sera. J Immunol Methods  2005,301(1-2),154-163","journal-title":"J Immunol Methods"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","volume":"14","author":"Stadler J.A.M.","year":"2023","unstructured":"Stadler J.A.M.; Maartens G.; Meintjes G.; Wasserman S.; Clofazimine for the treatment of tuberculosis. Front Pharmacol  2023,14,1100488","journal-title":"Front Pharmacol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11094-020-02239-2","volume":"54","author":"Kayukova L.A.","year":"2020","unstructured":"Kayukova L.A.; Berikova E.A.; Modern anti-tuberculosis drugs and their classification. Part I: First-line drugs. Pharm Chem J  2020,54(6),555-563","journal-title":"Pharm Chem J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bmcl.2016.11.084","volume":"27","author":"Chetty S.","year":"2017","unstructured":"Chetty S.; Ramesh M.; Singh-Pillay A.; Soliman M.E.S.; Recent advancements in the development of anti-tuberculosis drugs. Bioorg Med Chem Lett  2017,27(3),370-386","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/antibiotics9090550","volume":"9","author":"Mourenza \u00c1.","year":"2020","unstructured":"Mourenza \u00c1.; Gil J.A.; Mateos L.M.; Letek M.; Novel treatments against Mycobacterium tuberculosis based on drug repurposing. Antibiotics  2020,9(9),550","journal-title":"Antibiotics"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1368-7646(98)80028-9","volume":"1","author":"Barry C.E.","year":"1998","unstructured":"Barry C.E.; Slayden R.A.; Mdluli K.; Mechanisms of isoniazid resistance in Mycobacterium tuberculosis Drug Resist Updat  1998,1(2),128-134","journal-title":"Drug Resist Updat"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2200214","DOI":"10.1002\/ardp.202200214","volume":"355","author":"Reddy D.S.","year":"2022","unstructured":"Reddy D.S.; Sinha A.; Kumar A.; Saini V.K.; Drug re\u2010engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery. Arch Pharm (Weinheim)  2022,355(11),2200214","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"17362","DOI":"10.1021\/acsomega.2c05511","volume":"8","author":"Sharma K.","year":"2023","unstructured":"Sharma K.; Ahmed F.; Sharma T.; Grover A.; Agarwal M.; Grover S.; Potential Repurposed drug candidates for tuberculosis treatment: Progress and update of drugs identified in over a decade. ACS Omega  2023,8(20),17362-17380","journal-title":"ACS Omega"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/jac\/dkr173","volume":"66","author":"Almeida Da Silva P.E.","year":"2011","unstructured":"Almeida Da Silva P.E.; Palomino J.C.; Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: Classical and new drugs. J Antimicrob Chemother  2011,66(7),1417-1430","journal-title":"J Antimicrob Chemother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/resp.13304","volume":"23","author":"Lange C.","year":"2018","unstructured":"Lange C.; Chesov D.; Heyckendorf J.; Leung C.C.; Udwadia Z.; Dheda K.; Drug\u2010resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology  2018,23(7),656-673","journal-title":"Respirology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"Yee D.","year":"2003","unstructured":"Yee D.; Valiquette C.; Pelletier M.; Parisien I.; Rocher I.; Menzies D.; Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med  2003,167(11),1472-1477","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jsps.2020.01.011","volume":"28","author":"Imam F.","year":"2020","unstructured":"Imam F.; Sharma M.; Khayyam K.U.; Al-Harbi N.O.; Rashid M.K.; Ali M.D.; Ahmad A.; Qamar W.; Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs. Saudi Pharm J  2020,28(3),316-324","journal-title":"Saudi Pharm J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","volume":"38","author":"Ramachandran G.","year":"2015","unstructured":"Ramachandran G.; Swaminathan S.; Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf  2015,38(3),253-269","journal-title":"Drug Saf"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"253","DOI":"10.18203\/issn.2454-2156.IntJSciRep20150955","volume":"1","author":"Rathod K.B.","year":"2015","unstructured":"Rathod K.B.; Borkar M.S.; Lamb A.R.; Suryavanshi S.L.; Surwade G.A.; Pandey V.R.; Adverse events among patients of multi drug resistant tuberculosis receiving second line anti TB treatment. Int J Sci Res  2015,1(6),253","journal-title":"Int J Sci Res"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"Dartois V.A.","year":"2022","unstructured":"Dartois V.A.; Rubin E.J.; Anti-tuberculosis treatment strategies and drug development: Challenges and priorities. Nat Rev Microbiol  2022,20(11),685-701","journal-title":"Nat Rev Microbiol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nm0307-290","volume":"13","author":"Ginsberg A.M.","year":"2007","unstructured":"Ginsberg A.M.; Spigelman M.; Challenges in tuberculosis drug research and development. Nat Med  2007,13(3),290-294","journal-title":"Nat Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-pharmtox-061008-103123","volume":"49","author":"Nguyen L.","year":"2009","unstructured":"Nguyen L.; Pieters J.; Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: Challenges in tuberculosis drug development. Annu Rev Pharmacol Toxicol  2009,49(1),427-453","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.tube.2010.03.003","volume":"90","author":"Ginsberg AM","year":"2010","unstructured":"Ginsberg AM; Tuberculosis drug development: Progress, challenges, and the road ahead. Tuberculosis (Edinb)  2010,90(3),162-167","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"871464","DOI":"10.3389\/fmicb.2022.871464","volume":"13","author":"Sharma S.","year":"2022","unstructured":"Sharma S.; Sharma D.; Kalia N.P.; Editorial: Approaches to address resistance, drug discovery, and vaccine development in Mycobacterium tuberculosis: Challenges and opportunities. Front Microbiol  2022,13,871464","journal-title":"Front Microbiol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"684200","DOI":"10.3389\/fimmu.2021.684200","volume":"12","author":"Estrada Garc\u00eda I.","year":"2021","unstructured":"Estrada Garc\u00eda I.; Hern\u00e1ndez Pando R.; Ivanyi J.; Editorial: Advances in immunotherapeutic approaches to tuberculosis. Front Immunol  2021,12,684200","journal-title":"Front Immunol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"557809","DOI":"10.3389\/fimmu.2020.557809","volume":"11","author":"Afkhami S.","year":"2020","unstructured":"Afkhami S.; Villela A.D.; D\u2019Agostino M.R.; Jeyanathan M.; Gillgrass A.; Xing Z.; Advancing immunotherapeutic vaccine strategies against pulmonary tuberculosis. Front Immunol  2020,11,557809","journal-title":"Front Immunol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1440-1843.2010.01739.x","volume":"15","author":"Dheda K.","year":"2010","unstructured":"Dheda K.; Schwander S.K.; Zhu B.; Van ZYL-SMIT R.N.; Zhang Y.; The immunology of tuberculosis: From bench to bedside. Respirology  2010,15(3),433-450","journal-title":"Respirology"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/0470846526.ch6","volume":"217","author":"Rook GA","year":"1998","unstructured":"Rook GA; Hernandez-Pando R; . Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Novartis Found Symp  1998,217,73-87","journal-title":"Novartis Found Symp"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1021\/acsinfecdis.1c00136","volume":"7","author":"Aqdas M.","year":"2021","unstructured":"Aqdas M.; Maurya S.K.; Pahari S.; Singh S.; Khan N.; Sethi K.; Kaur G.; Agrewala J.N.; Immunotherapeutic role of NOD-2 and TLR-4 signaling as an adjunct to antituberculosis chemotherapy. ACS Infect Dis  2021,7(11),2999-3008","journal-title":"ACS Infect Dis"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1172\/JCI136288","volume":"130","author":"Dorhoi A.","year":"2020","unstructured":"Dorhoi A.; Kotz\u00e9 L.A.; Berzofsky J.A.; Sui Y.; Gabrilovich D.I.; Garg A.; Hafner R.; Khader S.A.; Schaible U.E.; Kaufmann S.H.E.; Walzl G.; Lutz M.B.; Mahon R.N.; Ostrand-Rosenberg S.; Bishai W.; du Plessis N.; Therapies for tuberculosis and AIDS: Myeloid-derived suppressor cells in focus. J Clin Invest  2020,130(6),2789-2799","journal-title":"J Clin Invest"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fcimb.2018.00332","volume":"8","author":"du Plessis N.","year":"2018","unstructured":"du Plessis N.; Kotze L.A.; Leukes V.; Walzl G.; Translational potential of therapeutics targeting regulatory myeloid cells in tuberculosis. Front Cell Infect Microbiol  2018,8,332","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"eadf9556","DOI":"10.1126\/scitranslmed.adf9556","volume":"15","author":"Yan J.","year":"2023","unstructured":"Yan J.; Nielsen T.B.; Lu P.; Talyansky Y.; Slarve M.; Reza H.; Novakovic B.; Netea M.G.; Keller A.E.; Warren T.; DiGiandomenico A.; Sellman B.R.; Luna B.M.; Spellberg B.; A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens. Sci Transl Med  2023,15(716),eadf9556","journal-title":"Sci Transl Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","volume":"386","author":"Hall V.","year":"2022","unstructured":"Hall V.; Foulkes S.; Insalata F.; Kirwan P.; Saei A.; Atti A.; Wellington E.; Khawam J.; Munro K.; Cole M.; Tranquillini C.; Taylor-Kerr A.; Hettiarachchi N.; Calbraith D.; Sajedi N.; Milligan I.; Themistocleous Y.; Corrigan D.; Cromey L.; Price L.; Stewart S.; de Lacy E.; Norman C.; Linley E.; Otter A.D.; Semper A.; Hewson J.; D\u2019Arcangelo S.; Chand M.; Brown C.S.; Brooks T.; Islam J.; Charlett A.; Hopkins S.; Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med  2022,386(13),1207-1220","journal-title":"N Engl J Med"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"e03134-21","DOI":"10.1128\/mBio.03134-21","volume":"12","author":"Silv\u00e9rio D.","year":"2021","unstructured":"Silv\u00e9rio D.; Gon\u00e7alves R.; Appelberg R.; Saraiva M.; Advances on the role and applications of interleukin-1 in tuberculosis. MBio  2021,12(6),e03134-21","journal-title":"MBio"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"Dermani F.K.","year":"2019","unstructured":"Dermani F.K.; Samadi P.; Rahmani G.; Kohlan A.K.; Najafi R.; PD\u20101\/PD\u2010L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol  2019,234(2),1313-1325","journal-title":"J Cell Physiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"e20220504","DOI":"10.1084\/jem.20220504","volume":"219","author":"Amaral E.P.","year":"2022","unstructured":"Amaral E.P.; Foreman T.W.; Namasivayam S.; Hilligan K.L.; Kauffman K.D.; Barbosa Bomfim C.C.; Costa D.L.; Barreto-Duarte B.; Gurgel-Rocha C.; Santana M.F.; Cordeiro-Santos M.; Du Bruyn E.; Riou C.; Aberman K.; Wilkinson R.J.; Barber D.L.; Mayer-Barber K.D.; Andrade B.B.; Sher A.; GPX4 regulates cellular necrosis and host resistance in Mycobacterium tuberculosis infection. J Exp Med  2022,219(11),e20220504","journal-title":"J Exp Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"Chiesa R.","year":"2023","unstructured":"Chiesa R.; Georgiadis C.; Syed F.; Zhan H.; Etuk A.; Gkazi S.A.; Preece R.; Ottaviano G.; Braybrook T.; Chu J.; Kubat A.; Adams S.; Thomas R.; Gilmour K.; O\u2019Connor D.; Vora A.; Qasim W.; Base-Edited C.A.R.T.; Base-edited CAR T group. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med  2023,389(10),899","journal-title":"N Engl J Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"151951","DOI":"10.1016\/j.imbio.2020.151951","volume":"225","author":"Ferluga J.","year":"2020","unstructured":"Ferluga J.; Yasmin H.; Al-Ahdal M.N.; Bhakta S.; Kishore U.; Natural and trained innate immunity against Mycobacterium tuberculosis Immunobiology  2020,225(3),151951","journal-title":"Immunobiology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4049\/jimmunol.153.2.604","volume":"153","author":"Luxembourg A.T.","year":"1994","unstructured":"Luxembourg A.T.; Cooper N.R.; T cell-dependent, B cell-activating properties of antibody-coated small latex beads. A new model for B cell activation. J Immunol  1994,153(2),604-614","journal-title":"J Immunol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","volume":"18","author":"Tiberi S.","year":"2018","unstructured":"Tiberi S.; du Plessis N.; Walzl G.; Vjecha M.J.; Rao M.; Ntoumi F.; Mfinanga S.; Kapata N.; Mwaba P.; McHugh T.D.; Ippolito G.; Migliori G.B.; Maeurer M.J.; Zumla A.; Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis  2018,18(7),e183-e198","journal-title":"Lancet Infect Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"a017863","DOI":"10.1101\/cshperspect.a017863","volume":"5","author":"Seung K.J.","year":"2015","unstructured":"Seung K.J.; Keshavjee S.; Rich M.L.; Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med  2015,5(9),a017863","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1093\/infdis\/jiad564","volume":"230","author":"Zainabadi K.","year":"2023","unstructured":"Zainabadi K.; Vilbrun S.C.; Mathurin L.D.; Walsh K.F.; Pape J.W.; Fitzgerald D.W.; Lee M.H.; A bedaquiline, pyrazinamide, levofloxacin, linezolid, clofazimine second line regimen for tuberculosis displays similar early bactericidal activity as the standard rifampin based first line regimen. J Infect Dis  2023,230(2),e447","journal-title":"J Infect Dis"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1128\/JCM.01138-16","volume":"54","author":"Kaniga K.","year":"2016","unstructured":"Kaniga K.; Cirillo D.M.; Hoffner S.; Ismail N.A.; Kaur D.; Lounis N.; Metchock B.; Pfyffer G.E.; Venter A.; A multilaboratory, multicountry study to determine mic quality control ranges for phenotypic drug susceptibility testing of selected first-line antituberculosis drugs, second-line injectables, fluoroquinolones, clofazimine, and linezolid. J Clin Microbiol  2016,54(12),2963-2968","journal-title":"J Clin Microbiol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"Conradie F.","year":"2022","unstructured":"Conradie F.; Bagdasaryan T.R.; Borisov S.; Howell P.; Mikiashvili L.; Ngubane N.; Samoilova A.; Skornykova S.; Tudor E.; Variava E.; Yablonskiy P.; Everitt D.; Wills G.H.; Sun E.; Olugbosi M.; Egizi E.; Li M.; Holsta A.; Timm J.; Bateson A.; Crook A.M.; Fabiane S.M.; Hunt R.; McHugh T.D.; Tweed C.D.; Foraida S.; Mendel C.M.; Spigelman M.; Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N Engl J Med  2022,387(9),810-823","journal-title":"N Engl J Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","volume":"7","author":"Tweed C.D.","year":"2019","unstructured":"Tweed C.D.; Dawson R.; Burger D.A.; Conradie A.; Crook A.M.; Mendel C.M.; Conradie F.; Diacon A.H.; Ntinginya N.E.; Everitt D.E.; Haraka F.; Li M.; van Niekerk C.H.; Okwera A.; Rassool M.S.; Reither K.; Sebe M.A.; Staples S.; Variava E.; Spigelman M.; Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: A multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med  2019,7(12),1048-1058","journal-title":"Lancet Respir Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/idr13030074","volume":"13","author":"Amin A.","year":"2021","unstructured":"Amin A.; Vartanian A.; Yegiazaryan A.; Al-Kassir A.L.; Venketaraman V.; Review of the effectiveness of various adjuvant therapies in treating Mycobacterium tuberculosis Infect Dis Rep  2021,13(3),821-834","journal-title":"Infect Dis Rep"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12865-019-0317-9","volume":"20","author":"Desalegn G.","year":"2019","unstructured":"Desalegn G.; Tsegaye A.; Gebreegziabiher D.; Aseffa A.; Howe R.; Enhanced IFN-\u03b3, but not IL-2, response to Mycobacterium tuberculosis antigens in HIV\/latent TB co-infected patients on long-term HAART. BMC Immunol  2019,20(1),35","journal-title":"BMC Immunol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.3389\/fimmu.2019.02089","volume":"10","author":"Ji Z.","year":"2019","unstructured":"Ji Z.; Jian M.; Chen T.; Luo L.; Li L.; Dai X.; Bai R.; Ding Z.; Bi Y.; Wen S.; Zhou G.; Abi M.E.; Liu A.; Bao F.; Immunogenicity and safety of the M72\/AS01 Candidate vaccine against tuberculosis: A meta-analysis. Front Immunol  2019,10,2089","journal-title":"Front Immunol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"105352","DOI":"10.1016\/j.micinf.2024.105352","volume":"26","author":"Qu P.","year":"2024","unstructured":"Qu P.; Li X.; Liu W.; Zhou F.; Xu X.; Tang J.; Sun M.; Li J.; Li H.; Han Y.; Hu C.; Lei Y.; Pan Q.; Zhan L.; Absence of PD-L1 signaling hinders macrophage defense against Mycobacterium tuberculosis via upregulating STAT3\/IL-6 pathway. Microbes Infect  2024,26(5-6),105352","journal-title":"Microbes Infect"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.21873\/anticanres.14182","volume":"40","author":"Svaton M.","year":"2020","unstructured":"Svaton M.; Zemanova M.; Zemanova P.; Kultan J.; Fischer O.; Skrickova J.; Jakubikova L.; Cernovska M.; Hrnciarik M.; Jirousek M.; Krejci J.; Krejci D.; Bilek O.; Blazek J.; Hurdalkova K.; Barinova M.; Melichar B.; Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer. Anticancer Res  2020,40(4),2209-2217","journal-title":"Anticancer Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/mco2.82","volume":"2","author":"Fatima S","year":"2021","unstructured":"Fatima S; Kumari A; Dwivedi VP; Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals. MedComm  2021,2(4),494-513","journal-title":"MedComm"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3390\/antibiotics12030541","volume":"12","author":"Gautam S.","year":"2023","unstructured":"Gautam S.; Qureshi K.A.; Jameel Pasha S.B.; Dhanasekaran S.; Aspatwar A.; Parkkila S.; Alanazi S.; Atiya A.; Khan M.M.U.; Venugopal D.; Medicinal plants as therapeutic alternatives to combat Mycobacterium tuberculosis: A comprehensive review. Antibiotics  2023,12(3),541","journal-title":"Antibiotics"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"e202200267","DOI":"10.1002\/cbdv.202200267","volume":"19","author":"Swain S.S.","year":"2022","unstructured":"Swain S.S.; Hussain T.; Combined bioinformatics and combinatorial chemistry tools to locate drug\u2010Able Anti\u2010TB phytochemicals: A cost\u2010effective platform for natural product\u2010based drug discovery. Chem Biodivers  2022,19(11),e202200267","journal-title":"Chem Biodivers"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/jcm8081166","volume":"8","author":"Dara Y.","year":"2019","unstructured":"Dara Y.; Volcani D.; Shah K.; Shin K.; Venketaraman V.; Potentials of host-directed therapies in tuberculosis management. J Clin Med  2019,8(8),1166","journal-title":"J Clin Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1233630","DOI":"10.3389\/fimmu.2023.1233630","volume":"14","author":"Gupta P.K.","year":"2023","unstructured":"Gupta P.K.; Jahagirdar P.; Tripathi D.; Devarajan P.V.; Kulkarni S.; Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of Mycobacterium tuberculosis through induction of autophagy and augment anti-TB activity of isoniazid in RAW 264.7 macrophages. Front Immunol  2023,14,1233630","journal-title":"Front Immunol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"656419","DOI":"10.3389\/fimmu.2021.656419","volume":"12","author":"Ozturk M.","year":"2021","unstructured":"Ozturk M.; Chia J.E.; Hazra R.; Saqib M.; Maine R.A.; Guler R.; Suzuki H.; Mishra B.B.; Brombacher F.; Parihar S.P.; Evaluation of Berberine as an adjunct to TB treatment. Front Immunol  2021,12,656419","journal-title":"Front Immunol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"111634","DOI":"10.1016\/j.jep.2018.12.008","volume":"243","author":"Dwivedi V.P.","year":"2019","unstructured":"Dwivedi V.P.; Bhattacharya D.; Singh M.; Bhaskar A.; Kumar S.; Fatima S.; Sobia P.; Kaer L.V.; Das G.; Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection. J Ethnopharmacol  2019,243,111634","journal-title":"J Ethnopharmacol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1002\/ptr.7954","volume":"37","author":"Lin F.","year":"2023","unstructured":"Lin F.; Chen J.; Chen M.; Lin S.; Dong S.; Protective effect and possible mechanisms of resveratrol in animal models of osteoporosis: A preclinical systematic review and meta\u2010analysis. Phytother Res  2023,37(11),5223-5242","journal-title":"Phytother Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.sjbs.2021.10.037","volume":"29","author":"Al-Attar A.M.","year":"2022","unstructured":"Al-Attar A.M.; Hematological and biochemical investigations on the effect of curcumin and Thymoquinone in male mice exposed to Thioacetamide. Saudi J Biol Sci  2022,29(1),660-665","journal-title":"Saudi J Biol Sci"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/bio.3757","volume":"35","author":"Shaghaghi M.","year":"2020","unstructured":"Shaghaghi M.; Rashtbari S.; Vejdani S.; Dehghan G.; Jouyban A.; Yekta R.; Exploring the interactions of a Tb(III)\u2013quercetin complex with serum albumins (HSA and BSA): Spectroscopic and molecular docking studies. Luminescence  2020,35(4),512-524","journal-title":"Luminescence"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"756","DOI":"10.9721\/KJFST.2021.53.6.756","volume":"53","author":"Son E.S.","year":"2021","unstructured":"Son E.S.; Lee S.K.; Cho S.N.; Park H.R.; Lee J.S.; Anti-tuberculosis effects of frankincense through immune responses of Mycobacterium tuberculosis-infected macrophages. Korean J Food Sci Technol  2021,53(6),756-760","journal-title":"Korean J Food Sci Technol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tube.2014.04.007","volume":"94","author":"Sharma S.","year":"2014","unstructured":"Sharma S.; Kalia N.P.; Suden P.; Chauhan P.S.; Kumar M.; Ram A.B.; Khajuria A.; Bani S.; Khan I.A.; Protective efficacy of piperine against Mycobacterium tuberculosis Tuberculosis (Edinb)  2014,94(4),389-396","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"101114","DOI":"10.1016\/j.rechem.2023.101114","volume":"6","author":"Dey A.","year":"2023","unstructured":"Dey A.; Anand K.; Singh A.; Prasad R.; Barthwal R.; Binding-induced thermal stabilization of mosR and ndhA G-quadruplex comprising genes by emodin leads to downregulation and growth inhibition in Mtb: Potential as anti-tuberculosis drug. Results Chem  2023,6,101114","journal-title":"Results Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1166\/mex.2023.2354","volume":"13","author":"Zhang C.","year":"2023","unstructured":"Zhang C.; Song D.; Zhang L.; Liu L.; Zhu B.; Artemisinin promotes apoptosis of spinal tuberculosis macrophages by inhibiting NF- \u03ba B. Mater Express  2023,13(2),260-266","journal-title":"Mater Express"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"e1009805","DOI":"10.1371\/journal.ppat.1009805","volume":"17","author":"Singh D.K.","year":"2021","unstructured":"Singh D.K.; Tousif S.; Bhaskar A.; Devi A.; Negi K.; Moitra B.; Ranganathan A.; Dwivedi V.P.; Das G.; Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis. PLoS Pathog  2021,17(8),e1009805","journal-title":"PLoS Pathog"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"106809","DOI":"10.1016\/j.intimp.2020.106809","volume":"87","author":"Bhaskar A.","year":"2020","unstructured":"Bhaskar A.; Kumari A.; Singh M.; Kumar S.; Kumar S.; Dabla A.; Chaturvedi S.; Yadav V.; Chattopadhyay D.; Prakash Dwivedi V.; [6]-Gingerol exhibits potent anti-mycobacterial and immunomodulatory activity against tuberculosis. Int Immunopharmacol  2020,87,106809","journal-title":"Int Immunopharmacol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijtb.2021.09.016","volume":"69","author":"Vidya Raj C.K.","year":"2022","unstructured":"Vidya Raj C.K.; Venugopal J.; Muthaiah M.; Chadha V.K.; Brammacharry U.; Swappna M.; Sangeetha A.V.; Dhandapani S.P.; Kareedhi V.R.; Calivarathan L.; Karthick M.; Jayapal K.; In-vitro anti-Mycobacterium tuberculosis effect of Eugenol. Indian J Tuberc  2022,69(4),647-654","journal-title":"Indian J Tuberc"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.3390\/molecules23092381","volume":"23","author":"Sawicki R.","year":"2018","unstructured":"Sawicki R.; Golus J.; Przekora A.; Ludwiczuk A.; Sieniawska E.; Ginalska G.; Antimycobacterial activity of Cinnamaldehyde in a Mycobacterium tuberculosis(H37Ra) model. Molecules  2018,23(9),2381","journal-title":"Molecules"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/pathogens12030449","volume":"12","author":"Rodrigues G.C.S.","year":"2023","unstructured":"Rodrigues G.C.S.; dos Santos Maia M.; de Souza T.A.; de Oliveira Lima E.; dos Santos L.E.C.G.; Silva S.L.; da Silva M.S.; Filho J.M.B.; da Silva Rodrigues Junior V.; Scotti L.; Scotti M.T.; Antimicrobial potential of betulinic acid and investigation of the mechanism of action against nuclear and metabolic enzymes with molecular modeling. Pathogens  2023,12(3),449","journal-title":"Pathogens"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bmcl.2017.01.026","volume":"27","author":"Saharan V.D.","year":"2017","unstructured":"Saharan V.D.; Mahajan S.S.; Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis. Bioorg Med Chem Lett  2017,27(4),808-815","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1080\/15548627.2019.1582743","volume":"15","author":"Kim T.S.","year":"2019","unstructured":"Kim T.S.; Jin Y.B.; Kim Y.S.; Kim S.; Kim J.K.; Lee H.M.; Suh H.W.; Choe J.H.; Kim Y.J.; Koo B.S.; Kim H.N.; Jung M.; Lee S.H.; Kim D.K.; Chung C.; Son J.W.; Min J.J.; Kim J.M.; Deng C.X.; Kim H.S.; Lee S.R.; Jo E.K.; SIRT3 promotes antimycobacterial defenses by coordinating mitochondrial and autophagic functions. Autophagy  2019,15(8),1356-1375","journal-title":"Autophagy"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00894-021-04993-w","volume":"28","author":"Tembe N.","year":"2022","unstructured":"Tembe N.; Machaba K.E.; Ndagi U.; Kumalo H.M.; Mhlongo N.N.; Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase: A molecular modelling perspective. J Mol Model  2022,28(2),35","journal-title":"J Mol Model"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ijpvm.ijpvm_81_22","volume":"14","author":"Talebi A.","year":"2023","unstructured":"Talebi A.; Soltani R.; Khorvash F.; Jouabadi S.M.; The effectiveness of Silymarin in the prevention of anti-tuberculosis drug-induced hepatotoxicity: A randomized controlled clinical trial. Int J Prev Med  2023,14(1),48","journal-title":"Int J Prev Med"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"e10660","DOI":"10.1590\/1414-431x2020e10660","volume":"54","author":"Bedir F.","year":"2021","unstructured":"Bedir F.; Kocaturk H.; Turangezli O.; Sener E.; Akyuz S.; Ozgeris F.B.; Dabanlioglu B.; Suleyman H.; Altuner D.; Suleyman B.; The protective effect of lycopene against oxidative kidney damage associated with combined use of isoniazid and rifampicin in rats. Braz J Med Biol Res  2021,54(8),e10660","journal-title":"Braz J Med Biol Res"},{"key":"ref=156","first-page":"518","volume":"1","author":"Donald P.R.","year":"1997","unstructured":"Donald P.R.; Lamprecht J.H.; Freestone M.; Albrecht C.F.; Bouic P.J.; Kotze D.; van Jaarsveld P.P.; A randomised placebo-controlled trial of the efficacy of beta-sitosterol and its glucoside as adjuvants in the treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis  1997,1(6),518-522","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/9017021","volume":"2022","author":"Ma T.","year":"2022","unstructured":"Ma T.; Mao X.; Meng X.; Wang Q.; Ginsenoside Rg1 inhibits STAT3 expression by miR-15b-5p to attenuate lung injury in mice with type 2 diabetes mellitus-associated pulmonary tuberculosis. Evid Based Complement Alternat Med  2022,2022,1-9","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12088-022-01003-2","volume":"62","author":"Meng R","year":"2022","unstructured":"Meng R; Dong W; Gao J; Lu C; Zhang C; Liao Q; Chen L; Wu H; Hu J; Wei W; Jiang Z.; Clostridium, bacteroides and prevotella associates with increased fecal metabolites Trans-4-Hydroxy-L-proline and Genistein in active pulmonary tuberculosis patients during anti-tuberculosis chemotherapy with isoniazid-rifampin-pyrazinamide-ethambutol (HRZE). Indian J Microbiol  2022,62(3),374-383","journal-title":"Indian J Microbiol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3389\/fmicb.2017.02142","volume":"8","author":"Zhang Q.","year":"2017","unstructured":"Zhang Q.; Sun J.; Wang Y.; He W.; Wang L.; Zheng Y.; Wu J.; Zhang Y.; Jiang X.; Antimycobacterial and anti-inflammatory mechanisms of baicalin via induced autophagy in macrophages infected with Mycobacterium tuberculosis Front Microbiol  2017,8,2142","journal-title":"Front Microbiol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/ptr.5437","volume":"29","author":"Raju A.","year":"2015","unstructured":"Raju A.; Degani M.S.; Khambete M.P.; Ray M.K.; Rajan M.G.R.; Antifolate activity of plant polyphenols against Mycobacterium tuberculosis. Phytother Res  2015,29(10),1646-1651","journal-title":"Phytother Res"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.intimp.2015.12.027","volume":"31","author":"Guzm\u00e1n-Beltr\u00e1n S.","year":"2016","unstructured":"Guzm\u00e1n-Beltr\u00e1n S.; Rubio-Badillo M.\u00c1.; Ju\u00e1rez E.; Hern\u00e1ndez-S\u00e1nchez F.; Torres M.; Nordihydroguaiaretic acid (NDGA) and \u03b1-mangostin inhibit the growth of Mycobacterium tuberculosis by inducing autophagy. Int Immunopharmacol  2016,31,149-157","journal-title":"Int Immunopharmacol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"e00583-23","DOI":"10.1128\/spectrum.00583-23","volume":"11","author":"Kumari A","year":"2023","unstructured":"Kumari A; Pahuja I; Negi K; Ghoshal A; Mukopadhyay S; Agarwal M; Mathew B; Maras JS; Chaturvedi S; Bhaskar A; Dwivedi VP; Withaferin a protects against primary and recurrent tuberculosis by modulating mycobacterium-specific host immune responses. Microbiol Spectr  2023,11(2),e00583-23","journal-title":"Microbiol Spectr"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2272754","volume":"42","author":"Sarkar N.","year":"2023","unstructured":"Sarkar N.; Khanal P.; Rawat R.; Dey Y.N.; Roy K.K.; Rosmarinic acid and its derivative\u2019s duel as antitubercular agents: Insights from computational prediction to functional response in vitro. J Biomol Struct Dyn  2023,42(23),1-10","journal-title":"J Biomol Struct Dyn"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40203-015-0014-1","volume":"3","author":"Shilpi J.A.","year":"2015","unstructured":"Shilpi J.A.; Ali M.T.; Saha S.; Hasan S.; Gray A.I.; Seidel V.; Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora. In Silico Pharmacol  2015,3(1),10","journal-title":"In Silico Pharmacol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2217\/fmb-2017-0232","volume":"13","author":"Nakamura de Vasconcelos S.S.","year":"2018","unstructured":"Nakamura de Vasconcelos S.S.; Caleffi-Ferracioli K.R.; Hegeto L.A.; Baldin V.P.; Nakamura C.V.; Stefanello T.F.; Freitas Gauze G.; Yamazaki D.A.S.; Scodro R.B.L.; Siqueira V.L.D.; Cardoso R.F.; Carvacrol activity and morphological changes in Mycobacterium tuberculosis Future Microbiol  2018,13(8),877-888","journal-title":"Future Microbiol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"16328","DOI":"10.1038\/s41598-023-43708-4","volume":"13","author":"Szulczyk D.","year":"2023","unstructured":"Szulczyk D.; Wozi\u0144ski M.; Koli\u0144ski M.; Kmiecik S.; G\u0142ogowska A.; Augustynowicz-Kope\u0107 E.; Dobrowolski M.A.; Roszkowski P.; Struga M.; Ciura K.; Menthol- and thymol-based ciprofloxacin derivatives against Mycobacterium tuberculosis: In vitro activity, lipophilicity, and computational studies. Sci Rep  2023,13(1),16328","journal-title":"Sci Rep"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/1573406416666200619114124","volume":"17","author":"Elsaman T.","year":"2021","unstructured":"Elsaman T.; Mohamed M.S.; Eltayib E.M.; Abdalla A.E.; Mohamed M.A.; Xanthone: A promising antimycobacterial scaffold. Med Chem  2021,17(4),310-331","journal-title":"Med Chem"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"5.2.07","DOI":"10.1128\/microbiolspec.TNMI7-0034-2016","volume":"5","author":"Jeffries C.","year":"2017","unstructured":"Jeffries C.; Lobue P.; Chorba T.; Metchock B.; Kashef I.; Role of the health department in tuberculosis prevention and control\u2014legal and public health considerations. Microbiol Spectr  2017,5(2),5.2.07","journal-title":"Microbiol Spectr"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12905-015-0256-4","volume":"15","author":"Montesanti S.R.","year":"2015","unstructured":"Montesanti S.R.; Thurston W.E.; Mapping the role of structural and interpersonal violence in the lives of women: Implications for public health interventions and policy. BMC Womens Health  2015,15(1),100","journal-title":"BMC Womens Health"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"e059441","DOI":"10.1136\/bmjopen-2021-059441","volume":"12","author":"Dawson E.R.","year":"2022","unstructured":"Dawson E.R.; Stennett M.; Daly B.; Macpherson L.M.D.; Cannon P.; Watt R.G.; Upstream interventions to promote oral health and reduce socioeconomic oral health inequalities: A scoping review protocol. BMJ Open  2022,12(6),e059441","journal-title":"BMJ Open"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"170","DOI":"10.23749\/mdl.v111i3.9983","volume":"111","author":"Zellweger J.P.","year":"2020","unstructured":"Zellweger J.P.; Sotgiu G.; Corradi M.; Durando P.; The diagnosis of latent tuberculosis infection (LTBI): Currently available tests, future developments, and perspectives to eliminate tuberculosis (TB). Med Lav  2020,111(3),170-183","journal-title":"Med Lav"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"e00180-19","DOI":"10.1128\/cmr.00180-19","volume":"35","author":"Dookie N.","year":"2022","unstructured":"Dookie N.; Ngema S.L.; Perumal R.; Naicker N.; Padayatchi N.; Naidoo K.; The changing paradigm of drug-resistant tuberculosis treatment: Successes, pitfalls, and future perspectives. Clin Microbiol Rev  2022,35(4),e00180-19","journal-title":"Clin Microbiol Rev"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.3390\/molecules26092671","volume":"26","author":"Terreni M.","year":"2021","unstructured":"Terreni M.; Taccani M.; Pregnolato M.; New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives. Molecules  2021,26(9),2671","journal-title":"Molecules"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010355430250330074301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/241080\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010355430250330074301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:02:39Z","timestamp":1790226159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/241080\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":173,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010355430250330074301","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}